tbuckley/cabot-search huggingface dataset:
Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology
Authors: N.G. Martin, S. Defres, L. Willis, R. Beckley, H. Hardwick, A. Coxon, S. Kadambari, L.-M. Yu, X. Liu, U. Galal, K. Conlin, M.J. Griffiths, R. Kneen, S. Nadel, P.T. Heath, D.E. Kelly, T. Solomon, M. Sadarangani, A.J. Pollard
Journal: Journal of Infection (2024)

ObjectivesThe aims of this study were to assess aetiology and clinical characteristics in childhood meningitis, and develop clinical decision rules to distinguish bacterial meningitis from other similar clinical syndromes.MethodsChildren aged <16 years hospitalised with suspected meningitis/encephalitis were included, and prospectively recruited at 31 UK hospitals. Meningitis was defined as identification of bacteria/viruses from cerebrospinal fluid (CSF) and/or a raised CSF white blood cell count. New clinical decision rules were developed to distinguish bacterial from viral meningitis and those of alternative aetiology.ResultsThe cohort included 3,002 children (median age 2·4 months); 1,101/3,002 (36·7%) had meningitis, including 180 bacterial, 423 viral and 280 with no pathogen identified. Enterovirus was the most common pathogen in those aged <six months and 10-16 years, with Neisseria meningitidis and/or Streptococcus pneumoniae commonest at age six months–nine years. The Bacterial Meningitis Score had a negative predictive value of 95·3%. We developed two clinical decision rules, that could be used either before (sensitivity 82%, specificity 71%) or after lumbar puncture (sensitivity 84%, specificity 93%), to determine risk of bacterial meningitis.ConclusionsBacterial meningitis comprised 6% of children with suspected meningitis/encephalitis. Our clinical decision rules provide potential novel approaches to assist with identifying children with bacterial meningitis.FundingThis study was funded by the Meningitis Research Foundation, Pfizer and the NIHR Programme Grants for Applied Research.
Transketolase promotes MAFLD by limiting inosine-induced mitochondrial activity
Authors: Lingfeng Tong, Zhangbing Chen, Yangyang Li, Xinxia Wang, Changjie Yang, Yakui Li, Yemin Zhu, Ying Lu, Qi Liu, Nannan Xu, Sijia Shao, Lifang Wu, Ping Zhang, Guangyu Wu, Xiaoyu Wu, Xiaosong Chen, Junwei Fang, Renbing Jia, Tianle Xu, Bin Li, Liang Zheng, Junling Liu, Xuemei Tong
Journal: Cell Metabolism (2024)
Microbiome bacterial influencers of host immunity and response to immunotherapy
Authors: Yeganeh Yousefi, Kelly J. Baines, Saman Maleki Vareki
Journal: Cell Reports Medicine (2024)

The gut microbiota influences anti-tumor immunity and can induce or inhibit response to immune checkpoint inhibitors (ICIs). Therefore, microbiome features are being studied as predictive/prognostic biomarkers of patient response to ICIs, and microbiome-based interventions are attractive adjuvant treatments in combination with ICIs. Specific gut-resident bacteria can influence the effectiveness of immunotherapy; however, the mechanism of action on how these bacteria affect anti-tumor immunity and response to ICIs is not fully understood. Nevertheless, early bacterial-based therapeutic strategies have demonstrated that targeting the gut microbiome through various methods can enhance the effectiveness of ICIs, resulting in improved clinical responses in patients with a diverse range of cancers. Therefore, understanding the microbiota-driven mechanisms of response to immunotherapy can augment the success of these interventions, particularly in patients with treatment-refractory cancers.
Monitoring norepinephrine release in vivo using next-generation GRABNE sensors
Authors: Jiesi Feng, Hui Dong, Julieta E. Lischinsky, Jingheng Zhou, Fei Deng, Chaowei Zhuang, Xiaolei Miao, Huan Wang, Guochuan Li, Ruyi Cai, Hao Xie, Guohong Cui, Dayu Lin, Yulong Li
Journal: Neuron (2024)
Aphantasia and hyperphantasia: exploring imagery vividness extremes
Authors: Adam Zeman
Journal: Trends in Cognitive Sciences (2024)

The vividness of imagery varies between individuals. However, the existence of people in whom conscious, wakeful imagery is markedly reduced, or absent entirely, was neglected by psychology until the recent coinage of 'aphantasia' to describe this phenomenon. 'Hyperphantasia' denotes the converse – imagery whose vividness rivals perceptual experience. Around 1% and 3% of the population experience extreme aphantasia and hyperphantasia, respectively. Aphantasia runs in families, often affects imagery across several sense modalities, and is variably associated with reduced autobiographical memory, face recognition difficulty, and autism. Visual dreaming is often preserved. Subtypes of extreme imagery appear to be likely but are not yet well defined. Initial results suggest that alterations in connectivity between the frontoparietal and visual networks may provide the neural substrate for visual imagery extremes.
Ancient Genomes From Bronze Age Remains Reveal Deep Diversity and Recent Adaptive Episodes for Human Oral Pathobionts
Authors: Iseult Jackson, Peter Woodman, Marion Dowd, Linda Fibiger, Lara M Cassidy
Journal: Molecular Biology and Evolution (2024)

Abstract Ancient microbial genomes can illuminate pathobiont evolution across millenia, with teeth providing a rich substrate. However, the characterization of prehistoric oral pathobiont diversity is limited. In Europe, only preagricultural genomes have been subject to phylogenetic analysis, with none compared to more recent archaeological periods. Here, we report well-preserved microbiomes from two 4,000-year-old teeth from an Irish limestone cave. These contained bacteria implicated in periodontitis, as well as Streptococcus mutans, the major cause of caries and rare in the ancient genomic record. Despite deriving from the same individual, these teeth produced divergent Tannerella forsythia genomes, indicating higher levels of strain diversity in prehistoric populations. We find evidence of microbiome dysbiosis, with a disproportionate quantity of S. mutans sequences relative to other oral streptococci. This high abundance allowed for metagenomic assembly, resulting in its first reported ancient genome. Phylogenetic analysis indicates major postmedieval population expansions for both species, highlighting the inordinate impact of recent dietary changes. In T. forsythia, this expansion is associated with the replacement of older lineages, possibly reflecting a genome-wide selective sweep. Accordingly, we see dramatic changes in T. forsythia's virulence repertoire across this period. S. mutans shows a contrasting pattern, with deeply divergent lineages persisting in modern populations. This may be due to its highly recombining nature, allowing for maintenance of diversity through selective episodes. Nonetheless, an explosion in recent coalescences and significantly shorter branch lengths separating bacteriocin-carrying strains indicate major changes in S. mutans demography and function coinciding with sugar popularization during the industrial period.
Design and optimization of piperidine-substituted thiophene[3,2-d]pyrimidine-based HIV-1 NNRTIs with improved drug resistance and pharmacokinetic profiles
Authors: Yanying Sun, Zhenzhen Zhou, Zhongling Shi, Fabao Zhao, Minghui Xie, Zongji Zhuo, Erik De Clercq, Christophe Pannecouque, Dongwei Kang, Peng Zhan, Xinyong Liu
Journal: Acta Pharmaceutica Sinica B (2024)

HIV-1 reverse transcriptase (RT) has received great attention as an attractive therapeutic target for acquired immune deficiency syndrome (AIDS), but the inevitable drug resistance and side effects have always been major challenges faced by non-nucleoside reverse transcriptase inhibitors (NNRTIs). This work aimed to identify novel chemotypes of anti-HIV-1 agents with improved drug-resistance profiles, reduced toxicity, and excellent druggability. A series of diarylpyrimidine (DAPY) derivatives were prepared via structural modifications of the leads K-5a2 and 25a. Among them, 15a with dimethylphosphine oxide moiety showed the most prominent antiviral potency against all of the tested viral panel, being 1.6-fold (WT, EC50 = 1.75 nmol/L), 3.0-fold (L100I, EC50 = 2.84 nmol/L), 2.4-fold (K103N, EC50 = 1.27 nmol/L), 3.3-fold (Y181C, EC50 = 5.38 nmol/L), 2.9-fold (Y188L, EC50 = 7.96 nmol/L), 2.5-fold (E138K, EC50 = 4.28 nmol/L), 4.8-fold (F227L/V106A, EC50 = 3.76 nmol/L) and 5.3-fold (RES056, EC50 = 15.8 nmol/L) more effective than that of the marketed drug ETR. Molecular docking results illustrated the detailed interactions formed by compound 15a and WT, F227L/V106A, and RES056 RT. Moreover, 15a·HCl carried outstanding pharmacokinetic (t1/2 = 1.32 h, F = 40.8%) and safety profiles (LD50 > 2000 mg/kg), which demonstrated that 15a·HCl is a potential anti-HIV-1 drug candidate.
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy
Authors: Richard Lafayette, Sean Barbour, Rubeen Israni, Xuelian Wei, Necmi Eren, Jürgen Floege, Vivekanand Jha, Sung Gyun Kim, Bart Maes, Richard K.S. Phoon, Harmeet Singh, Vladimír Tesař, Celia J.F. Lin, Jonathan Barratt
Journal: Kidney International (2024)

Atacicept is a first-in-class, dual anti-B-cell Activation Factor–A Proliferation-Inducing Ligand fusion protein in clinical evaluation for treatment of IgA nephropathy. To compare efficacy and safety of atacicept versus placebo in patients with IgAN, this randomized, double-blind, placebo-controlled phase 2b clinical trial ORIGIN enrolled 116 individuals with biopsy-proven IgA nephropathy. Participants were randomized to atacicept 150, 75, or 25 mg versus placebo once weekly for up to 36 weeks. Primary and key secondary endpoints were changes in urine protein creatinine ratio based on 24-hour urine collection at weeks 24 and 36, respectively, in the combined atacicept 150 mg and 75 mg group versus placebo. The primary endpoint was met at week 24 as the mean urine protein creatinine ratio was reduced from baseline by 31% in the combined atacicept group versus 8% with placebo, resulting in a significant 25% reduction with atacicept versus placebo. At week 36, the key secondary endpoint was met as the mean urine protein creatinine ratio reduced from baseline by 34% in the combined atacicept group versus a 2% increase with placebo, resulting in a significant 35% reduction with atacicept versus placebo. The reduction in proteinuria was accompanied by stabilization in endpoint eGFR with atacicept compared to a decline with placebo at week 36, resulting in significant between-group geometric mean difference of 11%, approximating an absolute difference of 5.7 mL/min/1.73m 2. Endpoint galactose deficient IgA1 levels significantly decreased from baseline by 60% versus placebo. The safety profile of atacicept was like placebo. Thus, our results provide evidence to support a pivotal, phase 3 study of atacicept in IgA nephropathy.
RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors
Authors: Shanthi Ganesh, Min Ju Kim, Jenny Lee, Xudong Feng, Krisjanis Ule, Amy Mahan, Harini Sivagurunatha Krishnan, Zhe Wang, Maryam Yahyaee Anzahaee, Garima Singhal, Ilia Korboukh, Jennifer A Lockridge, Laura Sanftner, Rene Rijnbrand, Marc Abrams, Bob D Brown
Journal: Molecular Therapy (2024)

Malignant tumors are often associated with an immunosuppressive tumor microenvironment (TME), rendering most of them resistant to standard-of-care immune checkpoint inhibitors (CPIs). Signal transducer and activator of transcription 3 (STAT3), a ubiquitously expressed transcription factor, has well-defined immunosuppressive functions in several leukocyte populations within the TME. Since the STAT3 protein has been challenging to target using conventional pharmaceutical modalities, we investigated the feasibility of applying systemically delivered RNA interference (RNAi) agents to silence its mRNA directly in tumor-associated immune cells. In preclinical rodent tumor models, chemically stabilized acylated small interfering RNAs (siRNAs) selectively silenced Stat3 mRNA in multiple relevant cell types, reduced STAT3 protein levels, and increased cytotoxic T cell infiltration. In a murine model of CPI-resistant pancreatic cancer, RNAi-mediated Stat3 silencing resulted in tumor growth inhibition, which was further enhanced in combination with CPIs. To further exemplify the utility of RNAi for cancer immunotherapy, this technology was used to silence Cd274, the gene encoding the immune checkpoint protein programmed death-ligand 1 (PD-L1). Interestingly, silencing of Cd274 was effective in tumor models that are resistant to PD-L1 antibody therapy. These data represent the first demonstration of systemic delivery of RNAi agents to the TME and suggest applying this technology for immuno-oncology applications.
Follow-up blood cultures do not reduce mortality in hospitalized patients with Gram-negative bloodstream infection: a retrospective population-wide cohort study
Authors: Sean W.X. Ong, Jin Luo, Daniel J. Fridman, Samantha M. Lee, Jennie Johnstone, Kevin L. Schwartz, Christina Diong, Samir N. Patel, Derek MacFadden, Bradley Langford, Steven Y.C. Tong, Kevin A. Brown, Nick Daneman
Journal: Clinical Microbiology and Infection (2024)

ObjectivesThe utility of follow-up blood cultures (FUBCs) in patients with Gram-negative bloodstream infection (GN-BSI) is controversial. Observational studies have suggested significant mortality benefit, but may be limited by single-center designs, immortal time bias, and residual confounding. We examined the impact of FUBCs on mortality in patients with GN-BSI in a retrospective population-wide cohort study in Ontario, Canada.MethodsAdult patients with GN-BSI hospitalized between April-2017 and December-2021 were included. Primary outcome was all-cause mortality within 30 days. FUBC was treated as a time-varying exposure. Secondary outcomes were 90-day mortality, length of stay (LOS), and number of days alive and out of hospital at 30 (DAOH30) and 90 (DAOH90) days.Results34,100 patients were included; 8807 (25.8%) patients received FUBC, of which 966 (11.0%) were positive. Median proportion of patients receiving FUBC was 18.8% (interquartile range 10.0–29.7%, range 0–66.1%) across 101 hospitals; this correlated with positivity and contamination rate. 890 (10.1%) patients in the FUBC group and 2263 (8.9%) patients in the no FUBC group died within 30 days. In the fully-adjusted model, there was no association between FUBC and mortality (HR 0.97, 95% CI 0.90–1.04). Patients with FUBC had significantly longer LOS (median 11 vs 7 days; adjusted RR 1.18, 95% CI 1.16–1.21) and fewer DAOH30/DAOH90.ConclusionsFUBC collection in patients with GN-BSI varies widely across hospitals and may be associated with prolonged hospitalization without clear survival benefit. Residual confounding may be present given the observational design. Clear benefit should be demonstrated in a randomized trial before widespread adoption of routine FUBC.
Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study
Authors: Myeong Geun Choi, Gun Woo Son, Mi Young Choi, Jae Seob Jung, Jin Kyung Rho, Wonjun Ji, Byeong Gon Yoon, Jong-Min Jo, Yong Man Kim, Dae-Hyun Ko, Jae Cheol Lee, Chang-Min Choi
Journal: Journal for ImmunoTherapy of Cancer (2024)

Background Choosing treatments for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with osimertinib resistance is challenging. We evaluated the safety and efficacy of SNK01 (autologous natural killer (NK) cells) in combination with cytotoxic chemotherapy and/or cetuximab (an anti-EGFR monoclonal antibody) in treating EGFR-mutated NSCLC in this non-clinical and phase I/IIa clinical trial. Methods We developed a cell line-derived xenograft-humanized mouse model with an osimertinib-resistant lung cancer cell line. The mice were divided into four groups based on treatment (no treatment, cetuximab, SNK01, and combination groups) and treated weekly for 5 weeks. In the clinical study, 12 patients with EGFR-mutated NSCLC who failed prior tyrosine kinase inhibitor (TKI) received SNK01 weekly in combination with gemcitabine/carboplatin (n=6) or cetuximab/gemcitabine/carboplatin (n=6) and dose escalation of SNK01 following the “3+3” design. Results In the non-clinical study, an increase in NK cells in the blood and enhanced NK cell tumor infiltration were observed in the SNK01 group. The volume of tumor extracted after treatment was the smallest in the combination group. In the clinical study, 12 patients (median age, 60.9 years; all adenocarcinoma cases) received SNK01 weekly for 7–8 weeks (4×10 9 cells/dose (n=6); 6×10 9 cells/dose (n=6)). The maximum feasible dose of SNK01 was 6×10 9 cells/dose without dose-limiting toxicity. Efficacy outcomes showed an objective response rate of 25%, disease control rate of 100%, and median progression-free survival of 143 days. Conclusion SNK01 in combination with cytotoxic chemotherapy, including cetuximab, for EGFR-mutated NSCLC with TKI resistance was safe and exerted a potential antitumor effect. Trial registration number NCT04872634 .
From hemostasis to proliferation: Accelerating the infected wound healing through a comprehensive repair strategy based on GA/OKGM hydrogel loaded with MXene@TiO2 nanosheets
Authors: Xingan Qiu, Linxia Nie, Pei Liu, Xiaojiang Xiong, Fangye Chen, Xuezhe Liu, Pengzhen Bu, Bikun Zhou, Meijun Tan, Fangbiao Zhan, Xiufeng Xiao, Qian Feng, Kaiyong Cai
Journal: Biomaterials (2024)
The Evolving Concept of Secondary Mitral Regurgitation Phenotypes
Authors: Lukas Stolz, Philipp M. Doldi, Anna Sannino, Jörg Hausleiter, Paul A. Grayburn
Journal: JACC. Cardiovascular imaging (2024)

Conflicting results from 2 randomized clinical trials of transcatheter mitral valve edge-to-edge repair in secondary mitral regurgitation (SMR) have led to the recognition that SMR is a heterogeneous disease entity presenting with different functional and morphological phenotypes. This review summarizes the current knowledge on SMR caused primarily by atrial secondary mitral regurgitation (aSMR) and ventricular SMR pathology. Although aSMR is generally characterized by severe left atrial enlargement in the setting of preserved left ventricular anatomy and function, different patterns of mitral annular distortion cause different phenotypes of aSMR. In ventricular SMR, the relation of SMR severity to left ventricular dilation as well as the degree of pulmonary hypertension and right ventricular dysfunction are important phenotypic characteristics, which are key for a better understanding of prognosis and treatment response.
Factors Impacting Physician Prognostic Accuracy in Heart Failure Patients With Reduced Left Ventricular Ejection Fraction
Authors: Ana C. Alba, Tayler A. Buchan, Sudipta Saha, Steve Fan, Stephanie Poon, Susanna Mak, Abdul Al-Hesayen, Mustafa Toma, Shelley Zieroth, Kim Anderson, Catherine Demers, Faizan Amin, Liane Porepa, Sharon Chih, Nadia Giannetti, Valeria Rac, Heather J. Ross, Gordon H. Guyatt
Journal: JACC Heart Failure (2024)
Deep Learning-Derived Myocardial Strain
Authors: Alan C. Kwan, Ernest W. Chang, Ishan Jain, John Theurer, Xiu Tang, Nadia Francisco, Francois Haddad, David Liang, Alexandra Fábián, Andrea Ferencz, Neal Yuan, Béla Merkely, Robert Siegel, Susan Cheng, Attila Kovács, Márton Tokodi, David Ouyang
Journal: JACC. Cardiovascular imaging (2024)
First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial
Authors: Xiao-Peng Tian, Jun Cai, Yi Xia, Yu-Chen Zhang, Liang Wang, Pan-Pan Liu, Hui-Qiang Huang, Ya-Jun Li, Hui Zhou, Zhi-Ming Li, Jing Yang, Li-Qiang Wei, Qi-Hua Zou, Ying Huang, Jun Li, Li Ling, Wen-Long Zhong, Qing-Qing Cai
Journal: The Lancet Haematology (2024)
Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
Authors: Peter A Campochiaro, Robert Avery, David M Brown, Jeffrey S Heier, Allen C Ho, Stephen M Huddleston, Glenn J Jaffe, Arshad M Khanani, Stephen Pakola, Dante J Pieramici, Charles C Wykoff, Sherri Van Everen
Journal: The Lancet (2024)
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
Authors: Christina Reith, David Preiss, Lisa Blackwell, Jonathan Emberson, Enti Spata, Kelly Davies, Heather Halls, Charlie Harper, Lisa Holland, Kate Wilson, Alistair J Roddick, Christopher P Cannon, Robert Clarke, Helen M Colhoun, Paul N Durrington, Shinya Goto, Graham A Hitman, G Kees Hovingh, J Wouter Jukema, Wolfgang Koenig, Ian Marschner, Borislava Mihaylova, Connie Newman, Jeffrey L Probsfield, Paul M Ridker, Marc S Sabatine, Naveed Sattar, Gregory G Schwartz, Luigi Tavazzi, Andrew Tonkin, Stella Trompet, Harvey White, Salim Yusuf, Jane Armitage, Anthony Keech, John Simes, Rory Collins, Colin Baigent, Elizabeth Barnes, Jordan Fulcher, William G Herrington, Adrienne Kirby, Rachel O'Connell, Pierre Amarenco, Hiroyuki Arashi, Philip Barter, D John Betteridge, Michael Blazing, Gerard J Blauw, Jackie Bosch, Louise Bowman, Eugene Braunwald, Richard Bulbulia, Robert Byington, Michael Clearfield, Stuart Cobbe, Björn Dahlöf, Barry Davis, James de Lemos, John R Downs, Bengt Fellström, Marcus Flather, Ian Ford, Maria Grazia Franzosi, John Fuller, Curt Furberg, Robert Glynn, Uri Goldbourt, David Gordon, Antonio Gotto, Jr, Richard Grimm, Ajay Gupta, C Morton Hawkins, Richard Haynes, Hallvard Holdaas, Jemma Hopewell, Alan Jardine, John JP Kastelein, Sharon Kean, Patricia Kearney, George Kitas, John Kjekshus, Genell Knatterud, Robert H Knopp, Michael Koren, Vera Krane, Martin Landray, John LaRosa, Roberto Latini, Eva Lonn, Donata Lucci, Jean MacFadyen, Peter Macfarlane, Stephen MacMahon, Aldo Maggioni, Roberto Marchioli, Lemuel Moyé, Sabina Murphy, Andrew Neil, Enrico B Nicolis, Chris Packard, Sarah Parish, Terje R Pedersen, Richard Peto, Marc Pfeffer, Neil Poulter, Sara Pressel, Jeffrey Probstfield, Mahboob Rahman, Michele Robertson, Frank Sacks, Roland Schmieder, Patrick Serruys, Peter Sever, John Shaw, James Shepherd, Lara Simpson, Peter Sleight, Liam Smeeth, Jonathan Tobert, Gianni Tognoni, John Varigos, Christoph Wanner, Hans Wedel, Stephen Weis, K Michael Welch, John Wikstrand, Lars Wilhelmsen, Stephen Wiviott, Junichi Yamaguchi, Robin Young, Faiez Zannad
Journal: The Lancet Diabetes & Endocrinology (2024)

Previous meta-analyses of summary data from randomised controlled trials have shown that statin therapy increases the risk of diabetes, but less is known about the size or timing of this effect, or who is at greatest risk. We aimed to address these gaps in knowledge through analysis of individual participant data from large, long-term, randomised, double-blind trials of statin therapy.
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
Authors: Sandra P D'Angelo, Dejka M Araujo, Albiruni R Abdul Razak, Mark Agulnik, Steven Attia, Jean-Yves Blay, Irene Carrasco Garcia, John A Charlson, Edwin Choy, George D Demetri, Mihaela Druta, Edouard Forcade, Kristen N Ganjoo, John Glod, Vicki L Keedy, Axel Le Cesne, David A Liebner, Victor Moreno, Seth M Pollack, Scott M Schuetze, Gary K Schwartz, Sandra J Strauss, William D Tap, Fiona Thistlethwaite, Claudia Maria Valverde Morales, Michael J Wagner, Breelyn A Wilky, Cheryl McAlpine, Laura Hudson, Jean-Marc Navenot, Tianjiao Wang, Jane Bai, Stavros Rafail, Ruoxi Wang, Amy Sun, Lilliam Fernandes, Erin Van Winkle, Erica Elefant, Colin Lunt, Elliot Norry, Dennis Williams, Swethajit Biswas, Brian A Van Tine
Journal: The Lancet (2024)